Seclidemstat
- Generic Name
- Seclidemstat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23ClN4O4S
- CAS Number
- 1423715-37-0
- Unique Ingredient Identifier
- TYH386V3WJ
- Associated Conditions
- -
- Associated Therapies
- -
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 10
- Registration Number
- NCT05266196
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT04734990
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Salarius Pharmaceuticals, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT03600649
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath